Inxmed (shanghai) Co., Ltd.
Clinical trials sponsored by Inxmed (shanghai) Co., Ltd., explained in plain language.
-
New drug duo targets hard-to-treat KRAS G12D cancers
Disease control Recruiting nowThis study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or met…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 05:59 UTC
-
New drug duo aims to outshine standard therapy for KRAS G12C lung cancer
Disease control Recruiting nowThis study tests whether a combination of two experimental drugs (IN10018 and D-1553) works better than the usual treatment for people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. About 400 adults who have not had prior treatment for t…
Phase: PHASE3 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called IN10018 combined with standard chemotherapy in people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based drugs. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC